KOL and Payer Assessment for a Development-Stage Oncology Therapy Across the US and Key European Markets

A large biotech company had a promising oncology therapy in phase 2 of development. To inform the development and strategic planning processes, it needed to understand the bar for success from the perspectives of oncologists and payers across the US and 3 key European markets

Our team leveraged a step-wise approach to build a holistic understanding of the disease area, as well as the implications on the bar for success. We began by conducting in-depth discussions with the client team (and secondary research) to gather the necessary context and background knowledge. Next, we conducted primary research with KOLs in the US and EU to gather input on the target product profile and insights on the bar for success, as well as potential areas of differentiation. We followed that with primary research with US and EU payers to get their thoughts on the future bar for success and understand potential pricing and access outcomes. Finally, we synthesized the research and provided recommendations for the client’s development program.

As a result of our work, the company was prepared to move its development program forward with confidence. Blue Matter was retained to continue assisting the company as it advanced the asset toward launch.